Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Giustini, R"'
Autor:
Madeddu, G., De Socio, G. V. L., Ricci, E., Quirino, T., Orofino, G., Carenzi, L., Franzetti, M., Parruti, G., Martinelli, C., Vichi, F., Penco, G., Dentone, C., Celesia, B. M., Maggi, P., Libertone, R., Bagella, P., Di Biagio, A., Quirino T, Bonfanti P., Bonfanti, P, Ricci, E, Bellacosa, C, Maggi, P, Abeli, C, Menzaghi, B, Celesia, Bm, Cosentino, S, Grosso, C, Stagno, A, Cappelletti, A, Santoro, D, Car-radori, S, Ghinelli, F, Vichi, F, Mazzotta, F, Maria Annunziata, S, Martinelli, C, Giustini, R, Leoncini, F, Penco, G, Cassola, G, Di Biagio, A, Viscoli, C, Molteni, C, Farinazzo, M, Miccolis, S, Scalzini, A, Landonio, S, Melzi, S, Rizzardini, G, Valsecchi, L, Cordier, L, Rusconi, S, Franzetti, M, Galli, M, Rosella, E, Fioni, G, De Socio GV, Sgrelli, A, Baldelli, F, Mazzotta, E, Parruti, G, Adri-ani, B, Paladini, A, Bagella, P, Madeddu, G, Mura, Ms, Marconi, P, Libertone, R, Antinori, A, Den-tone, C, Ferrea, G, Guastavigna, M, Orofino, G, Cristina, G, Carcò, F, Migliorini, D, Armignacco, O.
Muscle alterations ranging from asymptomatic creatine phosphokinase (CPK) increases to rhabdomyolysis and central nervous system (CNS) symptoms have been reported in patients receiving raltegravir. Muscle symptoms and CPK increases were investigated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4914080e2b78d9be56821adfad0f52cd
http://hdl.handle.net/10281/294942
http://hdl.handle.net/10281/294942